Pre-made Abrezekimab benchmark antibody ( Fab, anti-IL13 therapeutic antibody, Anti-IL-13/P600 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-004

Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abrezekimab (formerly VR 942) a biologic immunomodulatory product, is being developed by UCB and Vectura Group for the treatment of severe inflammatory.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-004-1mg 1mg 3090
GMP-Bios-ab-004-10mg 10mg Inquiry
GMP-Bios-ab-004-100mg 100mg Inquiry
GMP-Bios-ab-004-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Abrezekimab biosimilar, Fab, Anti-IL13 Antibody: Anti-IL-13/P600 therapeutic antibody
INN Name Abrezekimab
TargetIL13
FormatFab
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesUCB
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedAsthma
Development Techna